ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Collection
Years
  • 1
    Publication Date: 2004-11-16
    Description: PNH, a rare disease in children, is caused by an acquired somatic mutation of the phosphatidyl-inositol glycan (GPI)class A (PIG-A) gene, followed by a survival-advantage of the PNH clone. This results in a deficiency of GPI-anchored proteins on the hematopoietic cells, making them more susceptible for attacks of the complement system, causing hemolysis and pancytopenia. Binding-impairment of coagulation-system-regulators increases thrombosis-risk. Until now, world-wide only 40 cases of pediatric PNH have been reported. Clinical data from Dutch cases from 1983–2003 were collected nation-wide and studied retrospectively. Diagnosis was confirmed by a decrease of GPI-linked anchor proteins on granulocytes and/or erythrocytes (CD24, CD66b/67, CD59, CD16). All 11 PNH patients (4 boys, 7 girls), with a median age of 11 years (range 6–14 years) presented with pancytopenia-related symptoms. Two cases showed clinical hemoglobinuria, and one developed thrombosis during the course of the disease. BM biopsies showed hypoplasia/aplasia (AA)(n=7) or MDS (n=4). All cases showed decreased percentages of the GPI-linked proteins, 3/8 showed positive acid-Ham tests, 5/6 showed positive sucrose-lysis tests. Seven patients received prednisolone, in 5 combined with androgens and in 4 with ATG. After initial treatment, 3 patients reached complete remission (CR), and 2 showed partial response (PR), 1 subsequently relapsed and was transplanted. Three died of disease related mortality, one showed spontaneous recovery of blood counts.In total 5 patients underwent BMT (5MUD/2MSD). Conditioning regimens were Busulphan/Melphalan/Cyclophosphamide (n=2) in MDS, and Cyclophosphamide/ low dose TBI (n=3) in AA. Three patients received additional anti-Tcell antibody therapy. Of the 5 BMT patients 4 in CCR (median follow-up: 6 years, 10 months (range 7 months-14 years)). One patient died post-BMT of intracranial hemorrhage. PNH, a rare but serious disease in children, should be considered in every child with aplastic anemia/hypoplastic MDS. Hemoglobinuria is not an obligatory presenting symptom. GPI-linked anchor protein analysis provides the most reliable diagnostic tool. If prednisolone/ATG/androgens is not effective, BMT should be considered even if no matched sibling donor is available.
    Print ISSN: 0006-4971
    Electronic ISSN: 1528-0020
    Topics: Biology , Medicine
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...